# OnCo record nct04652076 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04652076/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04652076", "NCT04652076" ;
  schema:name "GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab"@en ;
  schema:alternateName "GYNET"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab and Carboplatin in endometrial cancer and cervical cancer, run by NETRIS Pharma, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04652076/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04652076> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2020-12-14" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/np137/> ;
  onco:companies <https://onco.cc/companies/merck/> .